Evidence map›Paper›PMID 38508700›Full record

ArticleBMJ open respiratory research2024

A Step towards understanding coronary artery disease: a complication in idiopathic pulmonary fibrosis.

Rishav Sinha, Dhairya Nanavaty, Arij Azhar, Pradeep Devarakonda, Sohrab Singh, Rupa Garikipati, Ankushi Sanghvi, Suganya Manoharan, Gaurav Parhar, Kiran Zaman and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open respiratory research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Rishav SinhaInternal Medicine, Brooklyn Hospital Center, Brooklyn, New York, USA rishav1911@gmail.com.ORCID http://orcid.org/0009-0001-1026-7505
Dhairya NanavatyInternal Medicine, Brooklyn Hospital Center, Brooklyn, New York, USA.
Arij AzharPulmonary/Critical Care Medicine, Brooklyn Hospital Center, Brooklyn, New York, USA.
Pradeep DevarakondaCardiology, Brooklyn Hospital Center, Brooklyn, New York, USA.
Sohrab SinghCardiology, Brooklyn Hospital Center, Brooklyn, New York, USA.
Rupa GarikipatiPediatrics, Cooper University Health Care, Camden, New Jersey, USA.
Ankushi SanghviInternal Medicine, Saint Vincent Hospital, Worcester, Massachusetts, USA.
Suganya ManoharanCardiology, Brooklyn Hospital Center, Brooklyn, New York, USA.
Gaurav ParharPulmonary/Critical Care Medicine, Brooklyn Hospital Center, Brooklyn, New York, USA.
Kiran ZamanPulmonary/Critical Care Medicine, Brooklyn Hospital Center, Brooklyn, New York, USA.
Cesar Ayala-RodriguezCardiology, Brooklyn Hospital Center, Brooklyn, New York, USA.
Viswanath VasudevanInternal Medicine, Brooklyn Hospital Center, Brooklyn, New York, USA.
Sarath ReddyCardiology, Brooklyn Hospital Center, Brooklyn, New York, USA.
Louis GerolemouPulmonary/Critical Care Medicine, Brooklyn Hospital Center, Brooklyn, New York, USA.
Brooklyn Hospital Center · USCooper University Health Care · USSaint Vincent Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIdiopathic pulmonary fibrosis (IPF) is a relatively rare disease with increasing incidence trends. Cardiovascular disease is a significant complication in IPF patients due to the role of common proatherogenic immune mediators. The prevalence of coronary artery disease (CAD) in IPF and the association between these distinct pathologies with overlapping pathophysiology remain less studied. RESEARCH QUESTION: We hypothesised that IPF is an independent risk factor for CAD.

methodsWe conducted a retrospective case-control study using the national inpatient sample (2017-2019). We included adult hospitalisations with IPF after excluding other interstitial lung diseases and other endpoints of CAD, acute coronary syndrome and old myocardial infarction. We examined their baseline characteristics, such as demographic data, hospital characteristics and socioeconomic status. The prevalence of cardiac risk factors and CAD was also compared between hospitalisations with and without IPF. Univariate and multivariate regression analysis was further performed to study the odds of CAD with IPF. The cases of IPF in the study population were propensity-matched, after which generalised linear modelling analysis was performed to validate the findings.

resultsA total of 116 010 admissions were hospitalised in 2017-2019 with IPF, of which 55.6% were men with a mean age of 73 years. Adult hospitalisations with IPF were found to have a higher prevalence of diabetes mellitus (29.3% vs 24.0%; p<0.001), hypertension (35.6% vs 33.8%; p<0.001), hyperlipidaemia (47.7% vs 30.2%; p<0.0001) and tobacco abuse (41.7% vs 20.9%; p<0.001), while they had a lower prevalence of obesity (11.7% vs 15.3%; p<0.0001) compared with hospitalisations without IPF. Multivariate logistic regression analysis revealed 28% higher odds of developing CAD in IPF hospitalisations (OR -1.28; CI 1.22 to 1.33; p<0.001). Postpropensity matching, generalised linear modelling analysis revealed even higher odds of CAD with IPF (OR -1.77; CI 1.54 to 2.02; p<0.001)

conclusionsOur study found a higher prevalence of CAD in IPF hospitalisations and significantly higher odds of CAD among IPF cases. IPF remains a terminal lung disease that portends a poor prognosis, but addressing the cardiovascular risk factors in these patients can help reduce the case fatality rate due to the latter and potentially add to quality-adjusted life years.

Indexed as

Coronary Artery DiseaseIdiopathic Pulmonary FibrosisAdultAgedCase-Control StudiesFemaleHumansLungMaleRetrospective Studiesinflammationinterstitial fibrosissystemic disease and lungstobacco and the lung

Identifiers

PMID38508700
PMCPMC10961575
OpenAlexW4392984490

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.